再生医学市场规模、份额和成长分析：按产品、治疗领域和地区划分 - 产业预测，2024-2031

Regenerative Medicine Market Size, Share, Growth Analysis, By Product (Cell Therapy, Gene Therapy), By Therapeutic Area (Oncology, Musculoskeletal Disorders), By Region - Industry Forecast 2024-2031

出版日期: 2024年08月08日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球再生医学市场规模将达到95.9亿美元，从2023年的122亿美元成长到2031年的836亿美元，复合年增长率预计将成长27.2%。

再生医学的主要目标是恢復因各种原因而丧失的功能。这包括修復和更换因老龄化、疾病或受伤而受损的组织和器官，以及解决出生缺陷。与传统治疗不同，再生医学具有恢復更快等优点。干细胞疗法和富含血小板的血浆等技术可增强人体的自然癒合能力，加速受损组织的修復，减少发炎和疤痕组织的形成。包括内源干细胞刺激和用于轻微组织损伤的类器官移植在内的新兴技术预计将在未来几年推动市场成长。干细胞生物学的最新进展正在对再生医学产生重大影响。我们提供从成体细胞创建多功能细胞以及在受控条件下从这些干细胞培养微生物等创新，为创建用于修復和移植的功能性人体组织提供了新策略。政府的支持也是市场拓展的重要因素。欧盟（EU）和荷兰政府强调再生医学是一个重要的政策相关领域。在北美，由于社会老化，市场正在蓬勃发展。美国北卡罗来纳州组织工程与再生医学会正在积极推动该领域的研究与发展，NIH、CIRM等机构资助学术和转化研究。全球医疗保健支出的成长预计也将提振市场。然而，资讯有限、使用胚胎干细胞的伦理问题、高投资成本以及测试灵敏度和再现性问题等挑战可能会阻碍市场成长。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 义大利
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Novartis AG（Switzerland）
Biogen（US）
Sarepta Therapeutics, Inc.（US）
Gilead Sciences, Inc.（US）
Amgen, Inc.（US）
Smith & Nephew plc.（UK）
MEDIPOST Co., Ltd.（South Korea）
JCR Pharmaceuticals Co., Ltd（Japan）
Takeda Pharmaceutical Company（Japan）
CORESTEM Inc.（South Korea）
Orthocell Ltd.（Australia）
Mesoblast Ltd（Australia）
BioRestorative Therapies, Inc.（US）
Tegoscience（South Korea）
APAC Biotech（India）
Shenzhen SiBiono Genetech Co., Ltd.（China）
Aspect Biosystems（Canada）
Athersys, Inc.（US）
Terumo Corporation（Japan）
Vericel Corporation（US）

简介目录

Product Code: SQMIG35I2129

Global Regenerative Medicine Market size was valued at USD 9.59 Billion in 2022 and is poised to grow from USD 12.2 Billion in 2023 to USD 83.6 Billion by 2031, growing at a CAGR of 27.2% in the forecast period (2024-2031).

The primary aim of regenerative medicine is to restore function lost due to various causes. It involves repairing or replacing tissues and organs damaged by aging, disease, or injury, and addressing congenital abnormalities. Unlike traditional treatments, regenerative medicine offers advantages such as accelerated recovery. Techniques like stem cell therapy and platelet-rich plasma enhance the body's natural healing process, speed up the repair of damaged tissues, and reduce inflammation and scar tissue formation. Emerging methods, including endogenous stem cell stimulation and organoid transplantation for minor tissue injuries, are expected to drive market growth in the coming years. Recent advancements in stem cell biology have significantly impacted regenerative medicine. Innovations such as generating pluripotent stem cells from adult cells and cultivating microorganisms from these stem cells under controlled conditions have provided new strategies for creating functional human tissue for repair and transplantation. Government support is also a crucial factor in market expansion. The European Union and the Dutch government have emphasized regenerative medicine as a key area of policy relevance. In North America, the market is thriving due to the growing aging population. The North Carolina Tissue Engineering and Regenerative Medicine Society in the U.S. is actively promoting research and development in this field, while agencies like NIH and CIRM fund academic and translational research. Increasing global healthcare spending is also expected to boost the market. However, challenges such as limited information, ethical concerns over embryonic stem cell use, high investment costs, and issues with test sensitivity and reproducibility may hinder market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Regenerative Medicine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Regenerative Medicine Market Segmental Analysis

Global regenerative medicine market is segmented based on Product, Therapeutic Category, Distribution Channel and Region. Based on Product, the market is segmented into Cell Therapy (Stem Cell Therapy {Cell Transplantations, Stem Cell Therapy Products [Autologous Therapy, Allogeneic Therapy]}, Cell-based Immunotherapy), Gene Therapy, And Tissue Engineering. Based on Therapeutic Area, the market is segmented into Oncology, Musculoskeletal Disorders, Dermatology & Wound Care, Cardiovascular Diseases, Ophthalmology, Neurology, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Regenerative Medicine Market

The increasing investment in the regenerative medicine market has spurred extensive research and development efforts, with investors backing start-ups dedicated to creating innovative treatments and products. This financial support has fostered research collaborations and mergers within the industry. Additionally, government investment plays a significant role, facilitating the development of effective treatment options for various chronic diseases, including cancer, diabetes, and kidney disease, among others.

Restraints in the Global Regenerative Medicine Market

The high cost of therapies and the absence of standardized reimbursement policies are major challenges hindering market growth. For instance, many stem cell therapies are classified as experimental or investigational, leading to limited coverage under Medicare. This often results in substantial out-of-pocket expenses for patients, as Medicare only covers FDA-approved treatments like allogeneic transplants. The lack of comprehensive insurance coverage forces patients to either pay for treatments out of pocket or seek crowdfunding, which can delay access to necessary care and stifle market expansion. Additionally, the scarcity of approved drugs for a broad range of genetic disorders, coupled with their high costs, further limits market growth and accessibility.

Market Trends of the Global Regenerative Medicine Market

A key trend in the global regenerative medicine market is the strategic acquisition of companies by major players to enhance their research and development capabilities. The market encompasses innovative products derived from living cells, proteins, enzymes, antibodies, antibody-drug conjugates (ADCs), and genetic materials, which are crucial for developing lifesaving treatments for various chronic diseases. However, translating these advanced technologies into clinical practice often reveals a gap between theoretical potential and real-world application. To address this, leading companies are increasingly turning to acquisitions to bolster their R&D efforts and advance the development of diverse clinical applications.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Start-up Analysis
PESTEL Analysis
Customer & Buying Criteria Analysis
Supply Chain Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Regenerative Medicine Market by Product

Market Overview
Cell Therapy
- Stem Cell Therapy
  - Cell transplantations
  - Stem cell therapy products
    - Autologous therapy
    - Allogeneic therapy
- Cell-based Immunotherapy
Gene Therapy
Cosmetics Implants
Tissue Engineering

Regenerative Medicine Market by Therapeutic Area

Market Overview
Oncology
Musculoskeletal Disorders
Dermatology & Wound Care
Cardiovascular Diseases
Ophthalmology
Neurology
Others

Regenerative Medicine Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- Italy
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sarepta Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MEDIPOST Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JCR Pharmaceuticals Co., Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CORESTEM Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orthocell Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Ltd (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioRestorative Therapies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tegoscience (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
APAC Biotech (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen SiBiono Genetech Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspect Biosystems (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Terumo Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments